Dong-A ST to Present Preclinical Results of EGFR-Targeted Protein Degrader 'SC2073' at US Cancer Conference

Dong-A ST announced on April 28 that it will present preclinical results of 'SC2073 (IN-207039)', an EGFR (epidermal growth factor receptor) targeted protein degrader currently under joint research with HK inno.N.

The company will unveil these preclinical results through a poster presentation at the American Association for Cancer Research (AACR 2025), which is being held in Chicago, Illinois, United States, from April 25 to April 30.

AACR is considered one of the world's top three cancer societies, alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Experts and industry professionals from around the world gather at this conference to discuss a wide range of topics related to cancer treatment and new drug development.

At this conference, Dong-A ST will present preclinical research results for 'SC2073 (IN-207039)', an EGFR targeted protein degrader being developed for non-small cell lung cancer patients with EGFR resistance mutations. The company plans to introduce the latest research achievements aimed at overcoming resistance caused by EGFR mutations, as well as highlight the new potential of 'SC2073 (IN-207039)' in the treatment of non-small cell lung cancer.

EGFR is a protein present on the surface of cells in the human body that regulates cell growth and differentiation. When mutations occur in EGFR, abnormal cell proliferation can lead to non-small cell lung cancer. Even when using second- and third-generation EGFR inhibitors, treatment efficacy is reduced due to resistance mutations in EGFR, such as T790M and C797S.

'SC2073 (IN-207039)' acts on the allosteric binding site of EGFR and selectively degrades only mutant EGFRs that show resistance to existing non-small cell lung cancer therapies. 'Allosteric' means 'structurally different', referring to a site other than the enzyme's active site. Because it does not affect normal EGFR, side effects can be minimized. In addition, it can be administered once daily by mouth, providing convenience for patients.

A representative from Dong-A ST stated, "We expect SC2073 to become a better treatment option for patients with EGFR resistance mutations," and added, "We will focus our research and development capabilities to quickly complete preclinical studies and move on to the next stage, so that SC2073 can become a new breakthrough in the treatment of non-small cell lung cancer."

Meanwhile, in September 2023, Dong-A ST signed a joint research agreement with HK inno.N to develop a next-generation EGFR degrader targeting EGFR mutations in non-small cell lung cancer. By sharing Dong-A ST's protein degradation platform technology and HK inno.N's proprietary EGFR inhibitors under development, the two companies are continuing research and development with the goal of discovering innovative EGFR protein degrader candidates.